Creative Biolabs has expanded its antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1, a move that could accelerate research into human retroviruses. The Shirley, New York-based company announced the expansion on September 24, 2026, underscoring the continued importance of retrovirus research in virology, immunology, vaccine development, and diagnostic assay development.
Human retroviruses remain a significant global health challenge. HIV-1 accounts for the majority of infections worldwide, while HIV-2 presents unique clinical challenges due to its distinct genetic makeup and different disease progression rates. HTLV-1, another retroviral threat, is the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy. Research antibodies that target defined viral proteins are essential for studying viral entry, epitope recognition, immune responses, and diagnostic assay development.
At the forefront of HIV-1 research is the viral envelope. The gp140 protein, an uncleaved ectodomain of the HIV-1 envelope glycoprotein, is a primary target for broadly neutralizing antibodies and vaccine design. Creative Biolabs now offers an anti-gp140 HIV-1 antibody for research applications involving HIV-1 envelope biology, antigen recognition, and related assay development. For HIV-2, the company provides antibodies targeting gp36, an HIV-2 envelope-associated antigen. These reagents can be useful for studying antigen recognition, cross-reactivity, and the development and evaluation of HIV-2-focused assay concepts.
Beyond HIV, Creative Biolabs has added an anti-HTLV-1 gag p19 antibody intended for research applications such as Western blot, ELISA, and immunohistochemistry. HTLV-1 gag p19 is a viral core protein commonly investigated in studies of HTLV-1 biology, viral protein expression, and immune recognition, supporting research into HTLV-1 pathogenesis and related virology questions.
"Retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats," said a senior scientist at Creative Biolabs. "By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, we aim to give researchers additional options for studying viral proteins, antigen recognition, and assay development."
The expansion matters because reliable research reagents are foundational to advancing scientific understanding of retroviruses. Better tools can lead to improved diagnostic assays, deeper insights into viral mechanisms, and ultimately inform vaccine and therapeutic strategies. For the global research community, this broader portfolio may reduce bottlenecks in obtaining specialized antibodies, potentially speeding up discoveries in virology and infectious disease.
Creative Biolabs provides retrovirus-targeted antibodies and custom antibody development services for research applications in virology and infectious disease. For more information about the complete range of retrovirus-targeted antibodies and custom services, visit https://www.antibody-creativebiolabs.com/. The company notes that its products are for research use only and not for use in diagnostic or therapeutic procedures.
